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INTRODUCTION
Ischemic stroke is one of the most common forms of cere-
brovascular disorders and occupies a leading position in 
the morbidity and mortality of the population worldwide, 
and is therefore an important medical and social problem. 
It has been proved that endothelial dysfunction plays a key 
role in the mechanisms of ischemic stroke development, 
so this issue has recently become of great importance, has 
been actively researched by scientists all over the world, and 
its relevance has not subsided over the years [1]. Endotheli-
al dysfunction is defined as an imbalance in the production 
system and the functioning of numerous vascular factors 
that lead to disorders of the homeostasis of the vascular wall 
[2]. Endothelin-1 is an important regulator of vascular wall 
metabolism [3]. Interacting with specific endothelin type 
A receptors, еndothelin-1 exerts its potent vasoconstrictor 
effect, also promotes cell proliferation, adhesion, fibrosis, 
stimulation of free radical formation and thrombosis, in-
dicating not only the effect on blood pressure, but also a 
key role in the progression of endothelial disorders [4, 5].
The functioning of endothelin-1, of course, is determined 
by the structural features of its gene. Therefore, the study 
of the role of the single-nucleotide polymorphism of the 
еndothelin-1 gene (EDN1) in the development of ischemic 
atherothrombotic stroke (IAS) is of great importance.
The essence of the Lys198Asn (rs5370) polymorphism 
of the EDN1 gene lies in the replacement of guanine (G) 
purine by pyrimidine thymine (T) at the 5665th position 
of the gene, which is reflected on the 61th nucleotide of the 
5th exon and leads to amino acid replacement of lysine by 
asparagine in the 198th protein codon [6]. The presence 
of a minor allele at this polymorphic site is known to be 
associated with a higher level of endothelin-1 in blood 
plasma [7], and the Lys/Lys genotype is associated with its 
lowest level [8]. The investigated polymorphic variant of the 
EDN1 gene plays an important role in the development of 
endothelial dysfunction and is involved in the pathogen-
esis of a number of cardiovascular [9] and, in particular, 
cerebrovascular diseases [10, 11].
THE AIM 
The aim of the study was to investigate the association of 
Lys198Asn allelic polymorphism of the EDN1 gene with 
ischemic atherothrombotic stroke development.
MATERIALS AND METHODS
Venous blood of 170 patients with IAS (42.4 % of women and 
57.6 % of men) aged 40 to 85 years (mean age of (64.7 ± 0.73) 
years) was used for the study. The ischemic nature of the 
stroke was established on the basis of anamnesis and clinical 
picture of the disease, the results of CT-study of the brain. 
The pathogenetic variant of the stroke was determined 
according to the TOAST criteria based on the anamnesis 
data, the clinical course of the disease, the results of the ul-
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trasound doppler of the major arteries of the head, and the 
electrocardiogram [12]. Patients with lacunar, cardioembolic 
ischemic stroke and ischemic stroke of unclear etiology were 
excluded from the experimental group. 
The control group comprised 124 persons (36.3 % women 
and 63.7 % men, average age was 76.7 ± 0.93 years) without 
the history of stroke or other acute cerebrovascular pa-
thologies, myocardial infarction and other atherosclerosis 
complications were included to the control group. The 
groups did not differ in the ratio of two sexes (P = 0.294 
for the χ²-test), but the average age of the control group 
(76.7 ± 0.93 years) was significantly higher than that of the 
experimental one (P < 0.001) (Table I). 
The work was performed in accordance with the prin-
ciples of the Helsinki Declaration of the World Medical 
Association “Ethical Principles of Medical Research with 
the Involvement of a Human being as a Research Object”, 
Order No. 690 of the Ministry of Health of Ukraine (dated 
September 23, 2009) and approved by the Bioethics Com-
mission of the Medical Institute of Sumy State University. 
Prior to engaging in the study, all participants provided 
written informed consent.
For genotyping, venous blood was collected under sterile 
conditions in 2.7 ml monovets with potassium salt of eth-
ylenediaminetetraacetic acid (Sarstedt, Germany), frozen 
and stored at -20 °C. Lys198Asn (rs5370) polymorphism of 
the EDN1 gene was determined by polymerase chain reac-
tion (PCR) method followed by restriction fragment length 
analysis. The region of the specified gene was amplified using 
a pair of specific primers [13]. For amplification, 50-100 ng 
of DNA was taken and added to a mixture containing 5 μl 
of 5-fold PCR buffer, 1.5 mm of magnesium sulfate, 200 μM 
of a mixture of four nucleotide triphosphates, 20 pM of each 
primer and 1.0 U of Taq-polymerase («Thermo Scientific», 
USA), the volume was adjusted to 25 μl with deionized water.
PCR was performed in a GeneAmp PCR System 2700 ther-
mocycler («Applied Biosystems», USA). Amplification of the 
fragment of the 5th exon consisted of 35 cycles: denaturation 
– 94 °C (60 s), hybridization of primers – 61 °C (60 s) and 
elongation – 72 °C (45 s). For restriction 2 units of restric-
tion enzyme Сас81 («Thermo Scientific», USA) were used. 
If guanine was contained in the 5665 position of the EDN1 
gene, the amplifier, consisting of 262 base pairs, was cleaved 
by Cas81 restriction enzyme into two fragments – 189 and 73 
base pairs. In case of replacement of guanine with thymine, 
the restriction site for Сас81 was lost and one fragment of 
size 262 base pairs was formed (Fig. 1). The amplifications 
after restriction were separated in 2.5% agarose gel containing 
ethidium bromide. Horizontal electrophoresis (0.13 A; 160 V) 
was performed for 35 minutes. DNA visualization after elec-
trophoresis was performed using a transilluminator (Biocom, 
Russia). Statistical analysis was performed using SPSS-17.0. 
The values of Р < 0.05 were considered reliable.
RESULTS AND DISCUSSION
The genotyping of control group individuals by Lys198Asn 
polymorphism of the EDN1 gene allowed to establish 
the ratio of homozygotes by major allele (Lys/Lys), het-
erozygotes (Lys/Asn) and homozygotes by minor allele 
(Asn/Asn), which amounted to 63.7.0%; 32.3% and 4.0% 
respectively (Table II). The frequency of the major (Lys) 
allele was 0.8 and of the minor (Asn) was 0.2. Palagnyuk et 
al., examining the distribution of genotypes according to 
this polymorphism in the inhabitants of Podilskyi region 
of Ukraine, found that the frequency of the minor allele 
among the surveyed persons was equal to 0.202 [14], which 
coincides with our data. Similar results were obtained in 
the writings of other scientists for different populations. 
Maver et al. studied the distribution of allelic variants of 
the EDN1 gene by the Lys198Asn polymorphic site among 
the population of Slovenia [15]. According to the data ob-
tained, the ratio of homozygotes by major allele (Lys/Lys), 
heterozygotes (Lys/Asn) and homozygotes for minor allele 
(Asn/Asn) among almost healthy individuals was equal 
to 62,1; 34.2 and 3.7% respectively. The frequency of the 
minor allele was 0.21 and did not differ significantly from 
the control group of the Ukrainian population (P > 0.05). 
Scientists led by Gampenrieder examined the genotype 
frequency of Lys/Lys, Lys/Asn and Asn/Asn in the Austrian 
population, which was 63.8; 30.5 and 5.7%, respectively 
[16]. The frequency of the minor allele was 0.21 and also 
had no statistical differences with the Ukrainian popu-
lation. The same results were obtained by Okan et al. for 
Turkish residents, genotype distribution among them was: 
Lys/Lys – 61.2%, Lys/Asn – 34.9% and Asn/Asn – 3.9%. The 
minor allele was encountered at a frequency of 0.21 [17]. 
In terms of genotype distribution in the IAS patient 
group, it looks like this. Homozygotes by major allele (Lys/
Lys) – 48.2%, heterozygotes (Lys/Asn) – 39.4%, homozy-
gotes by minor allele (Asn/Asn) – 12.4%. Comparison of 
the data obtained with the results of genotyping of control 
group members showed that there is a reliable association 
between the IAS development and Lys198Asn allelic vari-
ants of the EDN1 gene, which makes this genetic factor 
an important predictor of endothelial dysfunction and 
cardiovascular disease development (χ2 = 9.757; Р = 0.008). 
This conclusion is confirmed by the fact that in the homo-
zygotes for the minor allele Lys198Asn polymorphic site 
of the endothelin-1 gene, the risk of IAS development is 4 
times higher than in the homozygotes for the major allele 
(P = 0.07; OR = 4.046).
For other populations, Japanese researchers led by 
Yamaguchi have suggested that the impact of gene poly-
morphisms associated with atherothrombotic cerebral 
infarction may differ between women and men, and may 
depend on the presence or absence of traditional risk 
factors for atherosclerosis. According to multivariable lo-
gistic regression analysis adjusted for age, BMI, smoking, 
arterial hypertension, hypercholesterolemia and diabetes, 
Lys198Asn polymorphism of the EDN1 gene has signifi-
cant association with ischemic atherothrombotic stroke in 
women. However, no such association was found in men 
[18]. Aslan et al. the effect of Lys198Asn polymorphism of 
the EDN1 gene on the development of ischemic stroke in a 
Turkish population was studied. There were no significant 
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Figure 1: Results of EDN1 rs5370 polymorphism restriction analysis. M-molecular marker (bp-base pairs); lanes 3, 4, 5, and 8- Lys/Lys genotype; lanes 
6, 7, 10, and 11- Lys/Asn genotype; lanes 1, 2, and 9- Asn/Asn genotype.
associations between this polymorphic site and the like-
lihood of stroke, and no significant changes in the results 
were taken into account such risk factors as smoking, alco-
hol consumption, hypertension and diabetes mellitus [19]. 
The study of the effect of Lys198Asn polymorphism 
on the main characteristics of IAS yielded the following 
results (Table III).
The development of IAS may be associated with lesions: 1) 
anterior, middle, and posterior cerebral arteries; 2) vertebral 
and basilar arteries, and 3) combined variants when multiple 
arteries from the above two groups are affected. The obtained 
results show that there is no dependence between the genotype 
of patients under studied polymorphism on the one hand and 
the areas of the arterial pool whose atherothrombotic changes 
lead to IAS – on the other (Table III). This pattern persists 
after taking into account gender differences, hypertension, 
and smoking. Somewhat different results were found in the 
distribution of IAS patients into subgroups depending on 
BMI. In subjects with BMI < 25 kg/m2, the ratio of homozy-
gotes by major allele (Lys/Lys), heterozygotes (Lys/Asn) and 
homozygotes by minor allele (Asn/Asn) with lesions of the 
anterior, middle, posterior cerebral arteries was 46.9; 46.9 and 
6.3%, with lesions of the vertebral and basilar arteries 40.0; 
60.0 and 0%, and patients with the combined option – 25.0; 
0 and 75.0% respectively. Therefore, a statistically significant 
association of Lys198Asn polymorphism with the IAS arterial 
pool in individuals with BMI < 25 kg/m2 (χ2 = 16.998; P = 
0.002) was detected. In subjects with BMI ≥ 25 kg/m2, the 
frequency of allelic variants in this polymorphic variant was 
not statistically significant (χ2 = 2.853; P = 0.583).
The severity of the clinical course distinguish IAS: mild, mod-
erate and severe. The analysis showed the absence of association 
of Lys198Asn single nucleotide polymorphism with the severity 
of IAS. It has also not been identified taking into account such 
risk factors as gender and BMI. Taking into account the influ-
ence of hypertension revealed the following. In subjects with 
normal blood pressure, there was no association between the 
Lys198Asn polymorphic variant and the severity of IAS (χ2 = 
3.577; P = 0.466). Among individuals with hypertension who 
underwent IAS of varying severity, genotype distribution was as 
Table I. General characteristics of the study population.
Indicator Patients with IAS(n = 170)
Control group
(n = 124) P
Age, years 64,7±0,73 76,7±0,93 <0,001
Sex, female/male 72/98 45/79 0,294*
Body weight (f ), kg 77,6±1,42 69,8±1,8 0,001
Body weight (m), kg 82,6±1,33 75,7±1,77 0,002
Height (f ), cm 163,6±0,65 156,1±1,26 <0,001
Height (m), cm 172,9±0,76 167,2±0,96 <0,001
BMI (f ), kg/m2 29,0±0,54 28,7±0,77 0,744
BMI (m), kg/m2 27,6±0,41 27,0±0,55 0,355
Systolic BP, mmHg  167±2,3 152,6±2,1 <0,001
Diastolic BP, mmHg 95,4±1,2 86,3±1,1 <0,001
Fasting glucose, mmol/L 5,92±0,12 5,29±0,06 <0,001
Note:  n - number of patients; f - women; m - men; BMI - body mass index; BP - blood pressure; P - the statistical significance of differences; 
* - according to the χ2 criterion.
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follows: mild – Lys/Lys – 58.5%, Lys/Asn – 31.7% and Asn/Asn 
– 9.8%; moderate – 44.0; 50.0 and 6.0%; severe – 27.0; 51.4 and 
21.6%, respectively (χ2 = 11.278; P = 0.024). Thus, in homozy-
gotes for minor alleles with hypertension, severe IAS was more 
common than mild or moderate.
Among those with no smoking habits, the genotype 
ratio (Lys/Lys, Lys/Asn, Asn/Asn) with a mild clinical 
course was 65.9; 24.4; 9.8%, moderate – 46.8; 44.7; 8.5% 
and severe – 28.1; 53.1; 18.8% (χ2 = 11.369; P = 0.023). 
Therefore, a significant association of endothelin-1 gene 
polymorphism with the severity of IAS in non-smokers 
was found. However, the results of this association were not 
reliable in smokers (χ2 = 1.078; P = 0.888). This suggests that 
smoking is such a significant risk factor that the impact of 
genetic factors on the severity of the clinical course of IAS 
is not significant and may mask the association between 
the studied polymorphism and stroke.
According to the results of the studies presented in Table 
III, Lys198Asn polymorphism of the EDN1 gene does not 
affect the incidence of recurrent cases of ischemic athero-
thrombotic stroke. Patients with significant risk factors 
such as gender, BMI, arterial hypertension, and smoking 
did not influence stroke recurrence.
The association of genotype of patients with Lys198Asn 
polymorphism with neurological manifestations of IAS 
was also investigated. The results of the analysis revealed 
the absence of dependence of the characteristics of the 
neurological picture of IAS from this polymorphic site. The 
main risk factors were not taken into account (P ˃ 0.05).
CONCLUSIONS
The genotype ratios of the endothelin-1 gene polymor-
phism studied were significantly different in patients with 
Table IІ. Distributions of genotypes and alleles in case and control groups.
Control IAS
Lys/Lys, n (%) 79 (63,7) 82 (48,2)
Lys/Asn, n (%) 40 (32,3) 67 (39,4)





Note:  n - number of patients; P - statistical significance of the difference according to the Pearson χ2-criterion
Table IІІ. Effect of Lys198Asn polymorphic variants of the EDN1 gene on the main IAS characteristics 
IAS characteristics Genotype
According to the arterial pool Lys/Lys Lys/Asn Asn/Asn
Anterior, middle and posterior cerebral arteries 65 (49,2 %) 53 (40,2 %) 14 (10,6 %)
Vertebral and basilar arteries 10 (41,7 %) 10 (41,7 %) 4 (16,7 %)
Combined variants 7 (50,0 %) 4 (28,6 %) 3 (21,4 %)
χ2 = 2,339; P = 0,674
According to the severity of the clinical course Lys/Lys Lys/Asn Asn/Asn
Mild 33 (60,0 %) 15 (27,3 %) 7 (12,7 %)
Moderate 31 (47,0 %) 29 (43,9 %) 6 (9,1 %)
Severe 18 (36,7 %) 23 (45,6 %) 8 (16,3 %)
χ2 = 7,249; P = 0,123
By recurrence Lys/Lys Lys/Asn Asn/Asn
Primary 48 (45,7 %) 44 (41,9 %) 13 (12,4 %)
Recurrent 34 (52,3 %) 23 (35,4 %) 8 (12,3 %)
χ2 = 0,795; P = 0,672
According to clinical manifestations Lys/Lys Lys/Asn Asn/Asn
Movement disorders 2 (50,0 %) 2 (50,0 %) 0
Sensory disorders 9 (32,1 %) 16 (57,1 %) 3 (10,7 %)
Sensory-motor disorders 71 (51,4 %) 49 (35,5 %) 18 (13,0 %)
χ2 = 5,291; P = 0,259
Note: The frequency of genotypes in absolute values and percentages is given. P - statistical significance of the difference according to the Pearson χ2-criterion.
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IAS and in control subjects. It is revealed that the Asn/Asn 
genotype carriers have a 4 times higher risk of developing 
IAS. The Lys198Asn polymorphic site of the EDN1 gene 
influences the characteristics of ischemic atherothrombotic 
stroke. The association of this polymorphism with the 
arterial pool, whose atherothrombotic changes lead to the 
development of IAS, was found in individuals with BMI < 
25 kg/m2. Lys198Asn polymorphism also affects the sever-
ity of IAS in persons with hypertension and non-smokers.
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